Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Enliven Therapeutics, Inc. - Common Stock
(NQ:
ELVN
)
22.39
-0.17 (-0.75%)
Streaming Delayed Price
Updated: 3:41 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Enliven Therapeutics, Inc. - Common Stock
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024
August 13, 2024
ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024
May 14, 2024
ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
April 11, 2024
Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data.
Via
Benzinga
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 11, 2024
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
Via
Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
April 11, 2024
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
April 09, 2024
Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho...
Via
Benzinga
Wall Street Mixed As Tech Stocks Fall, Fed Meeting Begins
March 19, 2024
Stocks are scattered midday Tuesday, as investors digest the semiconductor sector's pullback that's being led by the shares of Nvidia.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 19, 2024
Via
Benzinga
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 19, 2024
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.
Via
Benzinga
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
March 19, 2024
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 19, 2024
Via
Benzinga
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023
March 14, 2024
ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
February 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 16, 2024
Via
Benzinga
7 A-Rated Biotech Stocks for Your August Buy List
August 17, 2023
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge.
Via
InvestorPlace
Bears Reload On Mobileye After Sharp Gains In Stock Price
May 28, 2023
Short interest on Mobileye Global fell from 23.9% to 21.2% in the week following the company’s Q1 results and FY23 guidance cut on April 27. However, Mobileye shares are up 31% from those lows over the...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
March 29, 2023
Via
Benzinga
7 Biotech Stocks Sitting in the Sweet Spot
March 24, 2023
Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
March 03, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.